Terms of Reference

The use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force (ADF), with particular reference to:

(a) the current and past policies and practices for:

(i) prescribing Quinoline anti-malarial drugs to ADF personnel, and

(ii) identifying and reporting adverse drug reactions from Quinoline anti-malarial drugs among ADF personnel;

(b) the nature and extent of any adverse health effects of those who have taken Mefloquine/Tafenoquine on serving and former ADF personnel;

(c) the support available for partners, carers and families of personnel who experience any adverse health effects of Quinoline anti-malarial drugs;

(d) a comparison of international evidence/literature available on the impact of Quinoline anti-malarials;

(e) how other governments have responded to claims regarding Quinoline anti-malarials; and

(f) any other related matters.



Committee Secretariat contact:

Foreign Affairs, Defence and Trade Committee
Department of the Senate
PO Box 6100
Parliament House
Canberra ACT 2600

Phone: +61 2 6277 3535
fadt.sen@aph.gov.au

About this inquiry

Inquiry into the use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force.



Past Public Hearings

08 Nov 2018: Canberra
05 Nov 2018: Melbourne
15 Oct 2018: Canberra

more...

Inquiry Status

Report Tabled

Accessibility

We are committed to ensuring that everyone who wishes to can participate in the Committee’s inquiry. If you have accessibility requirements, please contact the Committee Secretariat.

Further information regarding accessibility can be found at www.aph.gov.au/Help/Accessibility